Clinical trial
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients…
NCT00002502 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00002502 |
|---|---|
| Title | Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome |
| Official title | BUSULFAN AND CYCLOPHOSPHAMIDE FOR CYTOREDUCTION OF PATIENTS WITH ACUTE AND CHRONIC LEUKEMIAS AND MYELODYSPLASTIC SYNDROMES UNDERGOING ALLOGENEIC BONE MARROW TRANSPLANTATION WHO CANNOT BE TREATED WITH TOTAL BODY IRRADIATION |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes |
| Intervention type | Drug, Procedure |
| Interventions | busulfan, cyclophosphamide, cytarabine, allogeneic bone marrow transplantation |
| Start date | Jul 1, 1992 |
| Primary completion | May 1, 2000 |
| Completion | May 1, 2000 |
| First posted | Jul 19, 2004 |
| Last update posted | Jun 27, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: